

#### Newsletter



Genetic Tumour Risk Syndromes (ERN GENTURIS)

December 2020 | www.genturis.eu

### **ERN GENTURIS - upcoming webinars and endorsed guidelines**

In this ERN GENTURIS newsletter you will find two updates:

- Endorsement of the Hereditary diffuse gastric cancer guideline
- Upcoming webinars

## Hereditary diffuse gastric cancer guideline endorsed by ERN GENTURIS

ERN GENTURIS endorsed an updated clinical practice guideline on Hereditary Diffuse Gastric Cancer (HDGC) by Vanessa R Blair et al (<a href="https://doi.org/10.1016/S1470-2045(20)30219-9">https://doi.org/10.1016/S1470-2045(20)30219-9</a>). ERN GENTURIS evaluated the HDGC guideline against international best practice, using the Appraisal of Guidelines for Research & Evaluation tool (AGREE II), to assess the quality and independence of the guideline according to the ERN GENTURIS policy (see also <a href="https://www.genturis.eu/l=eng/Clinical-practice-guidelines.html">https://www.genturis.eu/l=eng/Clinical-practice-guidelines.html</a>)



# Recognising PTEN hamartoma tumour syndrome for early cancer detection

9 December – 16:00 CET Prof. Nicoline Hoogerbrugge, Nijmegen

The speaker of this webinar will be

Nicoline Hoogerbrugge, professor in hereditary cancer and chair of ERN GENTURIS.

This lecture on PTEN hamartoma tumour syndrome (PHTS) is based on a long time experience of Nicoline Hoogerbrugge being a medical doctor of more than 130 PHTS patients. She will show the diversity of the clinical phenotype in relation to recognition and diagnosis. Additionally the lifetime risks of cancer as well as the surveillance program for early cancer detection will be discussed, according to the recent European guideline on PHTS that were published in the Eur J Hum Genet. 2020 (https://doi.org/10.1038/s41431-020-0651-7).

If you would like to attend this webinar, please register here.

#### **Gastrointestinal Polyposis Syndromes**

13 January - 16:00 CET Prof. Stefan Aretz, Bonn

Stefan Aretz is professor of Genetics of Familial Tumour Syndromes at the University of Bonn and will be the speaker of this webinar on gastrointestinal polyposis syndromes.

Several clinically characterised hereditary tumour predisposition syndromes with predominant manifestation in the gastrointestinal tract have been delineated within the



last decades and explained by germline mutations in specific tumour suppressor or DNA repair genes. While some syndromes are restricted to gastrointestinal neoplasms, others show a variety of extraintestinal lesions. A clinical diagnosis might be challenging in the absence of a distinct family history and in case of a mono-symptomatic course. However, multigene panel testing can uncover those cases. For most of the polyposis syndromes, well established and efficient surveillance programs are available while in others, consensus recommendations are still lacking. This review will address state-of-the-art diagnostic algorithms and discuss present surveillance and management strategies.

#### **Upcoming webinars:**

**9 December:** Recognising PTEN hamartoma tumour syndrome for early cancer detection – *Prof. Nicoline Hoogerbrugge* 

**13 January:** Gastrointestinal polyposis syndromes – *Prof. Stefan Aretz*.

**27 January:** Variants identified in tumours can be germline – when to refer for germline testing – *Prof. Kathleen Claes* 

**10 February**: Germline mutations as a therapeutic target in breast cancer - *Dr. Judith Balmaña* 

**24 February:** Cancer Genetic Counseling and previvorship in an Era of Rapid Change – *Ass. Prof. Ignacio Blanco* 

**17 March:** Von Hippel-Lindau Syndrome – *Prof. Eamonn Maher* 

**31 March:** Psycho-oncologic aspects of genetic tumour risk syndromes – *Prof. Yvonne Brandberg* 

For more information on these webinars or for registration, please visit the <u>ERN GENTURIS website</u>.

## **ERN GENTURIS Coordinating Center:**

Radboud university medical center The Netherlands

genturis@radboudumc.nl
https://www.genturis.eu

#### How to unsubscribe?

You received this newsletter because you are a contact of ERN GENTURIS. If you no longer wish to receive newsletters, please unsubscribe.



